1 / 12

Waiver Requests

Waiver Requests. Ken Harshman, MS, DVM April 2011. What needs to be included?.

octavius-buchanan
Télécharger la présentation

Waiver Requests

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Waiver Requests Ken Harshman, MS, DVM April 2011

  2. What needs to be included? • Form FDA 356v – this is a new requirement because if the information included in a waiver is accepted and we granted a waiver from the requirement to conduct in vivo bioequivalence. If you are granted a waiver, this information now supports your approval and CVM requires a 356v for information that supports an approval.

  3. What needs to be included? • Identify: • Proprietary name for the proposed generic new animal drug (if known) & the reference listed new animal drug (RLNAD) • Established names for both • The strengths, dosage form, and route of administration for the proposed generic and approved for the RLNAD • The indications for the proposed generic and approved for the RLNAD • The sponsor and NADA No. for the RLNAD • The species proposed for the generic and approved for the RLNAD

  4. What needs to be included? • Certificates of analysis for all of the components of your product (including information on the specifications used, e.g., USP,NF, EP, etc.) • A side by side comparison of generic and RLNAD formulations - • Formulations should contain same ingredients/same concentration (Q1/Q2) • If differences exist, provide justification/evidence that these differences will not affect bioequivalence • A justification for why your product should be granted a waiver • Patent and Exclusivity Information • Current labeling for the RLNAD • Draft or representative generic labeling

  5. Q1/Q2 is about sameness

  6. What needs to be included? • Qualitative (Q1) sameness • Contains the same inactive ingredients as the RLNAD • Quantitative (Q2) sameness • Concentration or amount of each of the inactive ingredients differs by no more than 5% of the corresponding ingredient in the RLNAD

  7. What needs to be included? • Any change in formulation can not affect absorption or availability of the active ingredient • Consider reverse engineering (deformulating) the RLNAD

  8. What needs to be included? • If applicable, the following as well: • pH range of generic product • Particle size of active ingredients • Presence and significance of polymorphs or entantiomers of the active ingredients

  9. What needs to be included? • Solubility data • Exception – If you are seeking a waiver for a soluble powder oral dosage form, you may include a statement making a commitment to meet solubility requirements for demonstrating bioequivalence as part of your CMC technical section. In that case, you do not have to provide solubility information in your waiver request. • Solubility data needed to fulfill a biowaiver request and that required to complete the CMC technical section for soluble oral dosage forms are identical and obtained by the same methods.

  10. New BE Policy • A non-aqueous solution or micellular solution could qualify for a biowaiver • Will be evaluated on a case-by-case basis • Requirements • Q1/Q2 • Additional characterization of physico-chemical properties, if requested • In vitro testing, if requested

  11. Common mistakes to avoid • Failure to justify how differences in the formulation do not adversely affect the bioequivalence of the generic product • Incomplete characterization of the proposed generic formulation • No side-by-side comparison of formulations • Improper identification of the RLNAD

  12. Questions?

More Related